Lobe Sciences Eyes Uplisting Opportunities to Enhance Shareholder Value | CSE:LOBE, OTCQB:LOBEF
Express News | Lobe Sciences Ltd - in Addition to up-Listing Opportunities Company Is Exploring Out-Licensing Strategies
Express News | Lobe Sciences Ltd - Company Exploring Alternative Value Creation Opportunities
Lobe Sciences Announces Update
Company Exploring Alternative Value Creation OpportunitiesConvertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding Stra
Wesley Ramjeet to Join Lobe Sciences' Board of Directors, Bringing Decades of Strategic Financial...
Lobe Sciences Strengthens Board With Appointment of Biopharma Veteran | CSE:LOBE, OTCQB:LOBEF
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
Physician, Fund Manager, Investor, InventorFormer Vice Chancellor at Vanderbilt University Medical CenterFormer Board Director For Renal Care Group and Kinetic ConceptsVANCOUVER, British Columbia--(BU
Lobe Sciences Appoints Dr Harry Jacobson to Its Board | CSE:LOBE, OTCQB:LOBEF
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
Lobe Sciences Ltd. ("Lobe" or the "Company") (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC ("Clearway"), a wholly owned subsidiary of Sancilio & Company ("Sancilio"), a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.
Lobe Sciences Announces Change of Control | CSE:LOBE, OTCQB:LOBEF
Lobe Sciences Provides Company Review of 2023
Lobe Sciences Provides Update on L-130 Clinical Program
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
Biopharmaceutical company Lobe Sciences Ltd. (LOBE.CSE), on Tuesday announced its lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-mon
Lobe Sciences Appoints CFO
Lobe Sciences Ltd. (LOBE.CSE) said Monday that it has named Mathew Lee chief financial officer of the company. Lee currently serves as president of Manning Lee Management Ltd., a management consulting
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement
Lobe Sciences Ltd. (LOBE.CSE), a North American biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases, overnight Thursday said that i
Lobe Sciences, Ltd. Provides Update on Vitamind
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discov
The Power Play by The Market Herald Releases New Interviews With ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / April 19, 2023 / The Power Play by The Market Herald has announced the release of new interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar G
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discove
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
Lobe Sciences Ltd. Announces Exclusive Collaboration With Quality Chemical Laboratories LLC
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and